Monopar Therapeutics Inc. Common Stock
MNPR
MNPR: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
moreShow MNPR Financials
Recent trades of MNPR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MNPR's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on MNPR's company Twitter account
Number of mentions of MNPR in WallStreetBets Daily Discussion
Recent insights relating to MNPR
Recent picks made for MNPR stock on CNBC
ETFs with the largest estimated holdings in MNPR
Flights by private jets registered to MNPR